Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF, Wen PY. Mellinghoff IK, et al. Among authors: peters kb. Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2. Clin Cancer Res. 2021. PMID: 34078652 Free PMC article. Clinical Trial.
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. Vredenburgh JJ, et al. Among authors: peters kb. Clin Cancer Res. 2011 Jun 15;17(12):4119-24. doi: 10.1158/1078-0432.CCR-11-0120. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531816 Free PMC article. Clinical Trial.
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS. Reardon DA, et al. Among authors: peters kb. Cancer. 2011 Dec 1;117(23):5351-8. doi: 10.1002/cncr.26188. Epub 2011 May 16. Cancer. 2011. PMID: 21590689 Free PMC article. Clinical Trial.
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.
Ruden E, Reardon DA, Coan AD, Herndon JE 2nd, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, Friedman AH, Friedman HS, Peters KB, Jones LW. Ruden E, et al. Among authors: peters kb. J Clin Oncol. 2011 Jul 20;29(21):2918-23. doi: 10.1200/JCO.2011.34.9852. Epub 2011 Jun 20. J Clin Oncol. 2011. PMID: 21690470 Free PMC article.
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS. Reardon DA, et al. Among authors: peters kb. J Neurooncol. 2011 Dec;105(3):621-7. doi: 10.1007/s11060-011-0631-4. Epub 2011 Jul 9. J Neurooncol. 2011. PMID: 21744079 Free PMC article. Clinical Trial.
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ. Desjardins A, et al. Among authors: peters kb. Cancer. 2012 Mar 1;118(5):1302-12. doi: 10.1002/cncr.26381. Epub 2011 Jul 26. Cancer. 2012. PMID: 21792866 Free article. Clinical Trial.
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Reardon DA, et al. Among authors: peters kb. J Neurooncol. 2012 Jan;106(2):409-15. doi: 10.1007/s11060-011-0687-1. Epub 2011 Sep 22. J Neurooncol. 2012. PMID: 21938530 Free PMC article. Clinical Trial.
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Reardon DA, et al. Among authors: peters kb. J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11. J Neurooncol. 2012. PMID: 21986722 Free PMC article. Clinical Trial.
119 results